PetVivo Holdings PETV

PetVivo Holdings, Inc. is an emerging biomedical device company focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals. The Company has a pipeline of seventeen products for the treatment of animals and humans. A portfolio of ten issued patents (consisting of six U. S. patents and four foreign patents), two U. S. patent applications, and six proprietary trade secrets protects the Company’s biomaterials, products, production processes and methods of use.

PetVivo Holdings, Inc. generates revenue primarily through the commercialization and licensing of its lead product, Spryng® with OsteoCushion® Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses. The Company commenced sales of Spryng® in the second quarter of fiscal 2022 and plans to increase commercialization efforts in the United States through sales representatives, clinical studies, and market awareness initiatives. Additionally, PetVivo Holdings, Inc. has entered into distribution agreements with entities such as MWI, Covetrus North America, Vedco Inc., and Clipper Distributing, LLC to market and sell its products, and has secured an exclusive licensing agreement with VetStem, Inc. to market and sell their PrecisePRP product for both canine and equine applications.

The company operates as one segment from its corporate headquarters in Edina, Minnesota.

PetVivo Holdings, Inc. operates in the veterinary medical device industry, specifically targeting the osteoarthritis market in companion animals such as dogs and horses. The Company positions itself as an alternative to traditional treatments like nonsteroidal anti-inflammatory drugs (NSAIDs), which only alleviate symptoms without addressing underlying joint degeneration. Its Spryng® product addresses the root cause of osteoarthritis by mimicking the composition and mechanical properties of natural cartilage, promoting tissue repair and improving joint biomechanics. Competitors in the animal health space include major pharmaceutical companies such as Zoetis, Inc., Merck Animal Health, Elanco, Bayer Animal Health, and Boehringer Ingelheim Animal Health, among others.

PetVivo Holdings, Inc. serves licensed veterinary practices in the United States, including those that treat companion animals such as cats, dogs, and horses. The Company’s distribution partners, including MWI, Covetrus North America, Vedco Inc., and Clipper Distributing, LLC, supply its products to these veterinary clinics and hospitals. All customers must be licensed veterinary practices to purchase and administer Spryng® and other products under the Company’s distribution agreements.